A 2019 evaluation of opioid use disorder treatment resources in rural Utah counties

被引:1
|
作者
Ragsdale, Russell J. [3 ]
Nickman, Nancy A. [1 ,2 ]
Slager, Stacey [4 ]
Fox, Erin R. [5 ,6 ]
机构
[1] Univ Utah, Pharmacotherapy, 30 S 2000 E,Rm 4930, Salt Lake City, UT 84112 USA
[2] Univ Utah Hlth, Pharm Serv, 50 North Med Dr, Salt Lake City, UT 84132 USA
[3] Univ Utah Hlth Midvalley Specialty Pharm, Ambulatory Pharm Serv, Murray, UT USA
[4] Univ Utah, Pharmacotherapy Outcomes Res Ctr, Salt Lake City, UT 84112 USA
[5] Univ Utah Hlth, Drug Informat & Support Serv, Salt Lake City, UT USA
[6] Univ Utah, Coll Pharm, Salt Lake City, UT 84112 USA
关键词
INVOLVED OVERDOSE DEATHS; UNITED-STATES; NONMEDICAL USERS; BUPRENORPHINE; ACCESS; DRUG;
D O I
10.1016/j.japh.2021.03.019
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: The opioid crisis significantly affects residents of rural communities who already experience poor health outcomes based on social determinants. Therefore, this project evaluated the reported availability and accessibility of opioid use disorder (OUD) treatment resources in rural Utah county pharmacies through a multistep process intended to estimate the distance (miles) to registered (waivered) OUD care providers and community pharmacies and, thus, the ability to fill prescriptions for OUD treatment medications. Methods: First, the United States Department of Agriculture Economic Research Service dichotomous classification scheme was used to identify nonmetropolitan counties. Second, online resources were used to identify the volume of waivered treatment providers and community pharmacies by county. Third, the driving distances to both resources were estimated according to ZIP Code and county. Finally, the immediate availability of filling a prescription for OUD treatment medications was determined by surveying community pharmacists in rural Utah counties. Results: Nineteen of the 29 Utah counties were identified as rural and included in the study. Pharmacists in 50 of the 75 viable pharmacies completed surveys (66.7% usable response rate). OUD treatment medications were immediately available for dispensing in 90% (45 of 50) of the responding pharmacies. Two of the 19 counties (10.5%) lacked a pharmacy, and 6 of the 19 counties (31.6%) lacked a registered OUD treatment provider. Driving distances ranged from 1 mile to 71 miles to the nearest pharmacy and from 1 mile to 96 miles to the nearest waivered treatment provider. Conclusion: OUD treatment medications were readily available in some but not all rural Utah pharmacies. However, geographic barriers may prevent reasonable access to treatment providers and pharmacies for residents of smaller, remote communities. (C) 2021 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:513 / 521
页数:9
相关论文
共 50 条
  • [21] Remotely delivered incentives to promote buprenorphine treatment engagement in out-of-treatment adults with opioid use disorder
    Holtyn, August F.
    Toegel, Forrest
    Novak, Matthew D.
    Leoutsakos, Jeannie-Marie
    Fingerhood, Michael
    Silverman, Kenneth
    DRUG AND ALCOHOL DEPENDENCE, 2021, 225
  • [22] Increasing Capacity for Treatment of Opioid Use Disorder in Rural Primary Care Practices
    Zittleman, Linda
    Curcija, Kristen
    Nease, Donald E., Jr.
    Fisher, Mary
    Dickinson, L. Miriam
    Thomas, John F.
    Espinoza, Ashley
    Sutter, Christin
    Ancona, Jennifer
    Holtrop, Jodi Summers
    Westfall, John M.
    ANNALS OF FAMILY MEDICINE, 2022, 20 (01) : 18 - 23
  • [23] Simulating the Simultaneous Impact of Medication for Opioid Use Disorder and Naloxone on Opioid Overdose Death in Eight New York Counties
    Cerda, Magdalena
    Hamilton, Ava D.
    Hyder, Ayaz
    Rutherford, Caroline
    Bobashev, Georgiy
    Epstein, Joshua M.
    Hatna, Erez
    Krawczyk, Noa
    El-Bassel, Nabila
    Feaster, Daniel J.
    Keyes, Katherine M.
    EPIDEMIOLOGY, 2024, 35 (03) : 418 - 429
  • [24] Effect of opioid use disorder training on the attitudes of emergency medicine providers toward treatment of opioid use disorder
    Creighton, Ashley
    Wascak, Kimberly
    Shecter, Jonathan D.
    Kruse, Maxwell
    Murray, Brian Patrick
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2025, 93 : 48 - 56
  • [25] Medication-Assisted Treatment Use Among Pregnant Women With Opioid Use Disorder
    Krans, Elizabeth E.
    Kim, Joo Yeon
    James, Alton Everette, III
    Kelley, David
    Jarlenski, Marian P.
    OBSTETRICS AND GYNECOLOGY, 2019, 133 (05): : 943 - 951
  • [26] Social Vulnerability and the Prevalence of Opioid Use Disorder Among Older Medicare Beneficiaries in US Counties
    Yang, Tse-Chuan
    Kim, Seulki
    Matthews, Stephen A.
    Shoff, Carla
    JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL SCIENCES, 2023, 78 (12): : 2111 - 2121
  • [27] A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States
    Lister, Jamey J.
    Weaver, Addie
    Ellis, Jennifer D.
    Himle, Joseph A.
    Ledgerwood, David M.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2020, 46 (03): : 273 - 288
  • [28] Associations Between Polysubstance Use Patterns and Receipt of Medications for Opioid Use Disorder Among Adults in Treatment for Opioid Use Disorder
    Ford, Becky R.
    Bart, Gavin
    Grahan, Brian
    Shearer, Riley D.
    Winkelman, Tyler N. A.
    JOURNAL OF ADDICTION MEDICINE, 2021, 15 (02) : 159 - 162
  • [29] Long-term treatment retention of an emergency department initiated medication for opioid use disorder program
    Reuter, Quentin R.
    Dos Santos, Amanda
    McKinnon, Jamie
    Gothard, David
    Jouriles, Nicholas
    Seaberg, David
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2022, 55 : 98 - 102
  • [30] Buprenorphine treatment for opioid use disorder: recent progress
    Parida, Suprit
    Carroll, Kathleen M.
    Petrakis, Ismene L.
    Sofuoglu, Mehmet
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (08) : 791 - 803